<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120915010841N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-08-24</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>Epidural effects on labor pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of bolus epidural injection and continuous epidural infusion of lidocaine 1% on pain, normal delivery and motor function in patients with epidural analgesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/32887</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the randomization method is used as a 4-block block. In this way, according to the sample size, 13 blocks of four are identified, and in each of these four blocks, two of each group will be written in the form of letters A or B. This means that two A and two B are written in each block, although the order of the writing of the four letters A and B will be different in each block. The periodic numbers table will then be used to determine the order of block selection, Blinding description: After determining the epidural space and placing the catheter in the epidural space, in both groups, the 10 ml lidocaine 1% plus 1 ml of sufentanil is injected through the epidural catheter placed behind the patient. Then, in the bolus group, every  one hour, 10 ml lidocaine 1%   through an epidural catheter is bolusly  injected into the epidural space  by anesthesiologist regularly until delivery.In the continuous infusion group, lidocaine 1% is infused through a continuous infusion pump at a rate of 10 ml / h into the epidural space until delivery. The questionnaire is then completed by an anesthetist nurse. In this study, the evaluator and the patient do not know the type of drug administration as bolus and continuous infusion.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Vaginal  delivery under epidural analgesia.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: In bolus group patients after receiving 500 ml of Ringer's serum and in sitting position, first with 18 G epidural needle (Tohy)   in L3-L4 space and using the loss of  resistance technique, we determine the epidural space. Then place the epidural catheter in the epidural space and In the bolus group, 10 ml of lidocaine 1% plus 1 ml of sufentanil is injected into the epidural space at the same time, and then every one hour 10 ml of lidocaine 1% is bolusly injected  into the epidural space regularly until delivery  by anesthesiologist. Intervention 2: Second intervention group:  After receiving 500 ml of Ringer's serum and in sitting position, the first  18G  epidural needle  (Tohy)  is  inserted into space L3-L4 and using the loss  of resistance technique, we determine  the epidural space. Then the epidural catheter is placed in the epidural space and in the continuous infusion group, at first, 10 ml of lidocaine 1% plus 1 ml of sufentanil   bolusly  is injected into the epidural space, and Lidocaine 1% is then infused continuously at a rate of 10 ml / hour with continuous infusion pump  that is adjusted by anesthesiologist and infused into the epidural space until delivery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Because the study is not finished yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nahid Manouchehrian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fatemieh Hospital, Pasdaran Street</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517789971</zip>
        <telephone>+98 81 3827 7012</telephone>
        <email>manuchehriann@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nahid Manouchehrian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fatemieh Hospital, Pasdaran Street</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517789971</zip>
        <telephone>+98 81 3827 7012</telephone>
        <email>manuchehriann@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with first pregnancy
Aged 16 to 45
Failure to receive previous analgesic
Vertex  presentation
ASA  physical status class 1 and 2</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Epidural anesthesia contraindications (coagulation problems, hypovolemia, localized infections, high ICP and anemia)
patients with ASA  physical status class 3 and  4
presence of lesions and skin infections on the  lumbar and back of the patient
patients with poor cooperation in performing of epidural analgesia
patients who did not cooperate to answer the questionnaire questions).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>074.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of spinal and epidural anaesthesia during labour and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: In bolus group patients after receiving 500 ml of Ringer's serum and in sitting position, first with 18 G epidural needle (Tohy)   in L3-L4 space and using the loss of  resistance technique, we determine the epidural space. Then place the epidural catheter in the epidural space and In the bolus group, 10 ml of lidocaine 1% plus 1 ml of sufentanil is injected into the epidural space at the same time, and then every one hour 10 ml of lidocaine 1% is bolusly injected  into the epidural space regularly until delivery  by anesthesiologist.</i_keyword>
      <i_keyword>Second intervention group:  After receiving 500 ml of Ringer's serum and in sitting position, the first  18G  epidural needle  (Tohy)  is  inserted into space L3-L4 and using the loss  of resistance technique, we determine  the epidural space. Then the epidural catheter is placed in the epidural space and in the continuous infusion group, at first, 10 ml of lidocaine 1% plus 1 ml of sufentanil   bolusly  is injected into the epidural space, and Lidocaine 1% is then infused continuously at a rate of 10 ml / hour with continuous infusion pump  that is adjusted by anesthesiologist and infused into the epidural space until delivery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Labor pain. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Using a Visual Analogue Scale,   that  patient marks his pain on a 10-cm ruler.</prim_outcome>
      <prim_outcome>Progress of labor. Timepoint: During labor. Method of measurement: Measurement of the duration of the first and second stages of labor.</prim_outcome>
      <prim_outcome>Motor function. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Using Bromage Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic  Blood  Pressure. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Noninvasive blood pressure monitoring.</sec_outcome>
      <sec_outcome>Diastolic Blood Pressure. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Noninvasive blood pressure monitoring.</sec_outcome>
      <sec_outcome>Mean Arterial Pressure. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Noninvasive blood pressure monitoring.</sec_outcome>
      <sec_outcome>Heart Rate. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Noninvasive blood pressure monitoring.</sec_outcome>
      <sec_outcome>Satisfaction. Timepoint: After baby birth. Method of measurement: Ask the patient about the amount of satisfaction.</sec_outcome>
      <sec_outcome>Total dose of lidocaine. Timepoint: After delivery and catheter exit. Method of measurement: Calculate the number of lidocaine ampoules.</sec_outcome>
      <sec_outcome>Newborn Apgar. Timepoint: The first and fifth minutes after birth. Method of measurement: Examination and calculation on Apgar score.</sec_outcome>
      <sec_outcome>Nausea &amp; Vomiting. Timepoint: During the first and second stages of labor. Method of measurement: Observation  and ask the patient.</sec_outcome>
      <sec_outcome>Sedation. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: Using  Ramsay Score.</sec_outcome>
      <sec_outcome>Pruritus. Timepoint: Before and after epidural analgesia and minutes 10, 20, 30, 40, 50, 60 after epidural analgesia and the onset and end of the second stage of labor. Method of measurement: VAS Of Pruritus.</sec_outcome>
      <sec_outcome>Paresthesia   of  Lip. Timepoint: During the first and second stages of labor. Method of measurement: Ask the patient.</sec_outcome>
      <sec_outcome>The amount of ephedrine consumed. Timepoint: After delivery and catheter exit. Method of measurement: Calculate the amount of ephedrine consumed in mg.</sec_outcome>
      <sec_outcome>Need to do cesarean section. Timepoint: After baby birth. Method of measurement: observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-06-30</approval_date>
        <contact_name>Ethics committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>Mahdie Street, Hamadan University of Medical Sciences Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
